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Abstract
Background: To evaluate the palliative role of radiotherapy (RT) and define the effectiveness of chemotherapy
combined with palliative RT (CCRT) in patients with a symptomatic pelvic mass of metastatic colorectal cancer.
Methods: From August 1995 to December 2007, 80 patients with a symptomatic pelvic mass of metastatic
colorectal cancer were treated with palliative RT at Samsung Medical Center. Initial presenting symptoms were pain
(68 cases), bleeding (18 cases), and obstruction (nine cases). The pelvic mass originated from rectal cancer in 58
patients (73%) and from colon cancer in 22 patients (27%). Initially 72 patients (90%) were treated with surgery,
including 64 complete local excisions; 77% in colon cancer and 81% in rectal cancer. The total RT dose ranged 8-
60 Gy (median: 36 Gy) with 1.8-8 Gy per fraction. When the a/b for the tumor was assumed to be 10 Gy for the
biologically equivalent dose (BED), the median RT dose was 46.8 Gy10 (14.4-78). Twenty one patients (26%) were
treated with CCRT. Symptom palliation was assessed one month after the completion of RT.
Results: Symptom palliation was achieved in 80% of the cases. During the median follow-up period of five months
(1-44 months), 45% of the cases experienced reappearance of symptoms; the median symptom control duration
was five months. Median survival after RT was six months. On univariate analysis, the only significant prognostic
factor for symptom control duration was BED ≥40 Gy10 (p < 0.05), and CCRT was a marginally significant factor
(p = 0.0644). On multivariate analysis, BED and CCRT were significant prognostic factors for symptom control
duration (p < 0.05).
Conclusions: RT was an effective palliation method in patients with a symptomatic pelvic mass of metastatic
colorectal cancer. For improvement of symptom control rate and duration, a BED ≥ 40 Gy10 is recommended
when possible. Considering the low morbidity and improved symptom palliation, CCRT might be considered in
patients with good performance status.
Keywords: metastatic colorectal cancer, pelvic recurrence, palliative radiation therapy, concurrent
chemoradiotherapy
Background
Local recurrence of colorectal cancer after surgery
occurred in 10-40% of patients [1-4]. Although local
control has been improved with adjuvant chemotherapy
and radiotherapy (RT), approximately 10-25% of patients
still develop recurrence of disease in the pelvis [5-7].
Pelvic recurrence contributes significantly to the clinical
course and is one of the major problems affecting the
quality of life in these patients [8,9].
The role of primary tumor resection for non-curable
stage IV colorectal cancer remains undefined. Kleespies
et al. reported that palliative resection was associated
with a particularly unfavorable outcome in rectal cancer
patients presenting with locally advanced lesion
expected macroscopic residual tumor or an extensive
comorbidity [10]. Patients with prior curative resection
* Correspondence: wonro.park@samsung.com
1Department of Radiation Oncology, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, Korea
Full list of author information is available at the end of the article
Bae et al. Radiation Oncology 2011, 6:52
http://www.ro-journal.com/content/6/1/52
© 2011 Bae et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.of colorectal cancer often present with pelvic pain, one
of the common manifestations of local recurrence invol-
ving nerves in the presacrum or pelvic sidewalls. The
surgical approach to relieve symptomatic pain in the
pelvis is usually unlikely to have negative resection mar-
gins [11]. Accordingly, resection of symptomatic pelvic
tumor may be warranted only in those with adequate
performance status and a resectable tumor burden with
a possibly negative resection margin.
RT has been considered an effective palliative treat-
ment for patients with symptomatic pelvic tumors of
colorectal cancer. Previous studies have used RT as pal-
liative treatment to relieve pelvic symptoms in heteroge-
neous patients [9,11-23]. These studies included patients
with unresectable local recurrence after definitive sur-
gery and symptomatic local recurrence with distant
metastasis. Recently, modern combination chemotherapy
including targeted drugs has been used to treat patients
with metastatic colorectal cancer patients [24,25].
Although these drugs might be effective for sympto-
matic palliation in responding patients, the role of RT in
addition to chemotherapeutic or targeted drugs for pal-
liation is controversial. To date, there have been few
reports of the synergistic effect of concurrent chemora-
diotherapy (CCRT) with palliative intent in gastrointest-
inal cancer [22,26-30].
In this study, we evaluated the palliative role of RT
and defined the effectiveness of chemotherapy combined
with palliative RT in patients with a symptomatic pelvic
mass of metastatic colorectal cancer.
Methods
From August 1995 to December 2007, we retrospec-
tively reviewed 80 patients with a symptomatic pelvic
mass of metastatic colorectal cancer who were treated
with palliative RT at Samsung Medical Center. All
patients had disease outside the pelvis and consulted a
radiation oncologist for symptomatic palliation.
Fifty-eight patients (73%) were initially diagnosed with
rectal cancer and 22 patients (27%) with colon cancer.
Seventy-two patients (90%) were treated with surgery,
including 64 complete local excisions (52 curative sur-
geries). Eight patients (10%) received chemotherapy
alone. Twenty-two patients (27%) received adjuvant RT
after curative surgery or salvage RT after local recur-
r e n c e .T h eR Td o s er a n g e df r o m4 0 G yt o7 4 G yw i t h
1.8-2.0 Gy per fraction.
Patient age at the time of palliative RT for symptomatic
pelvic mass ranged from 27 to 85 years (median 57 years).
There were 43 males (54%) and 37 females (46%). Eastern
Cooperative Oncology Group (ECOG) performance scores
were 0 in one patient (1%), 1 in 28 (35%), 2 in 36 (45%), 3
in 13 (16%), and 4 in two (3%) patients. Forty patients
(50%) had single organ metastasis regardless of the
number of metastatic nodules, and 40 patients (50%) had
two or more organ metastases. The common metastatic
sites were liver (33 patients, 41%), lung (29, 36%), paraaor-
tic lymph node (27, 34%), and peritoneal seeding (15, 19%).
Eighty patients had 95 cases of clinical symptoms. The
most common clinical symptom was pain (68, 72%),
followed by rectal bleeding in 18 cases (19%), and
obstructive symptoms in nine cases (9%). Six patients
had two concurrent symptoms, pain and bleeding (five
patients) or pain and obstruction (one patient). Seven
patients experienced pain recurrence after palliative RT
and received palliative re-RT. In these patients, evalua-
tion of the response to palliative re-RT was available,
and all cases were independently included in the analysis
of symptom response to palliative RT.
RT was administered using 6-15 MV photon beams
from linear accelerators. The radiation field included the
recurrent mass of the pelvic cavity with 2-3 cm margins.
Different RT doses were used according to the patient’s
performance status and extra-pelvic tumor burden. The
median RT dose was 36 Gy (8-60 Gy). All patients
received RT once daily, and the dose per fraction ranged
from 1.8 Gy to 8.0 Gy (median 2.5 Gy). The total RT
doses were converted into the biologically equivalent
dose (BED) for comparison. When a/b was assumed to
be 10 Gy, the median total BED was 46.8 Gy10 (14.4-
78.0 Gy10).
Twenty-one patients (26%) received CCRT with the
following regimens: capecitabine in eight patients, fluor-
ouracil in six patients, oral tegafur-uracil in five patients,
and combination regimen in two patients. Thirty-one
cases received further chemotherapy after completion of
palliative RT. Patient and treatment characteristics are
shown in Table 1.
Symptom palliation was assessed one month after the
completion of palliative RT. For patients with pain as
the presenting symptom, effective palliation was defined
as decreased or resolved pain or decreased analgesia.
For patients with bleeding, effective palliation was
defined as improved hemoglobin, stable hemoglobin,
resolved hematochesia, or normalized hemoglobin. For
patients with obstruction, effective palliation was defined
as improved or resolved constipation, decreased laxative
use, or no need for intervention such as a stent or
colostomy.
T h ef o l l o w - u pp e r i o dw a sd e f i n e da st h et i m ef r o m
the start of palliative RT until progression of symptom
or death. Toxicity was assessed according to the Com-
mon Terminology Criteria for Adverse Events (CTCAE)
version 3.0.
Survival rates were estimated with the Kaplan-Meier
method, and comparisons between the groups were
determined using the log-rank test [31]. Multivariate
analysis was performed to assess the relationships
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using the Cox proportional hazards model [32]. The
Chi-square test was used to analysis differences in
patient and treatment characteristics between the symp-
tom control group and the recurrent group. Statistical
analyses were performed using SAS software (SAS for
Windows, version 9.0, SAS Institute, Cary, NC, USA).
Results
The median follow-up time was five months (range, 1-
44 months). The overall survival rate at one year was
22.1%, and the median survival was six months. Overall
symptomatic palliation was achieved in 76 of 95 cases
(80%). Forty-three cases (45%) experienced recurrence
of symptoms, and the median symptom control duration
was five months (range, 1-44 months).
In 80 patients, 68 cases had the symptom of pain; 54
cases (79%) achieved palliation of pain and 35 cases
(51%) experienced reappearance of pain. Eighteen cases
had the symptom of bleeding; 15 cases (83%) achieved
palliation of bleeding and five cases (28%) experienced
reappearance of bleeding. Nine cases had the symptom
of obstruction; seven cases (78%) achieved palliation of
obstruction, and three cases (33%) experienced reap-
pearance of obstruction.
Figure 1 shows symptom control rates according to
initial presenting symptom. One-year symptomatic con-
trol rates were 32.1%, 69.9%, and 37.5% for pain, bleed-
ing, and obstruction, respectively. Table 2 shows the
recurrence rate after symptom palliation. BED was a sta-
tistically significant factor affecting recurrence after
symptom palliation (p = 0.0011). For BED < 40 Gy10, 23
of 34 cases (68%) had recurrence and for BED ≥ 40
Gy10, and 20 of 61 cases (33%) had recurrence.
On univariate analysis, the only significant prognostic
factor for symptom control rate was BED (p = 0.0089),
and CCRT was a marginally significant factor (p =
0.0644) (Table 3). In patients with pain, higher BED and
CCRT was associated with improved outcome with sta-
tistical significance. In patients with bleeding, only
higher BED was statistically significant factor. In nine
patients with obstruction, there was no significant factor
associated with symptom relief. Figure 2 shows differ-
ences in the symptom control rate according to BED
and CCRT. Multivariate Cox regression analysis of prog-
nostic factors for the symptom control rate revealed that
higher RT dose (BED ≥ 40 Gy10, hazard ratio; 0.503, p =
0.0406) and CCRT (hazard ratio; 0.427, p = 0.0449)
were favorable factors.
All patients tolerated the palliative treatment. Thirty-
eight patients experienced nausea, diarrhea, cystitis, or
perineal skin reaction of grade 1 or 2 during treatment.
There was no significant difference of treatment related
toxicity between RT alone and CCRT (45% vs. 52%, p =
0.4380). There was no severe toxicity above grade 3 or
treatment-related deaths.
Discussion
External RT has been considered an effective palliative
treatment in patients with an unresectable pelvic mass
of colorectal cancer. Studies reported in the 1960s-
1980s showed that relief of pain and/or bleeding was
achieved in approximately 75% of patients with doses as
low as 20 Gy in ten fractions over two weeks or various
doses of 40-60Gy in 1.8-2.5 Gy per fraction [11-20].
Median duration of symptom relief was only 6-9
months. Later reports showed similar or improved
results of symptom palliation: control of pain in 78-93%
of patients, control of bleeding in 68-100%, and control
of mass in 35-88% [9,21-23]. The rate and duration of
symptom palliation in our study were similar to those
of previous reports.
Table 1 Patient and treatment characteristics
Characteristic No. of patients (%)
Age Median: 57 years
< 60 years 43 (54)
≥ 60 years 37 (46)
Gender
Male 43 (54)
Female 37 (46)
ECOG* performance status
0-2 65 (81)
3-4 15 (19)
Primary site
Colon cancer 22 (27)
Rectal cancer 58 (73)
Status of distant metastasis
Single organ involved 40 (50)
Multiple organs involved 40 (50)
Symptom
b
Pain 68 (72)
Bleeding 18 (19)
Obstruction 9 (9)
Re-irradiation
†
Yes 30 (32)
No 65 (68)
Biologically equivalent dose
†
<4 0G y 10 34 (36)
≥ 40 Gy10 61 (64)
Concurrent chemotherapy
†
Yes 22 (23)
No 73 (77)
Adjuvant chemotherapy
†
Yes 31 (33)
No 64 (67)
* ECOG: Eastern Cooperative Oncology Group.
†Treatment characteristics: 80 patients had 95 cases of clinical symptoms.
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Figure 1 Symptom control rates according to initial presenting symptom. (a) pain, (b) bleeding, (c) obstruction.
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the effect of palliation. Wong CS et al. [9] reported the
response rate of pelvic symptoms according to RT dose.
There was a trend suggesting increased response rates
with increasing total RT dose. For pain improvement
after RT, 48% of patients responded after a total dose of
less than 20 Gy, 77% responded after a dose of 20-30
Gy, 79% after 30-45 Gy, and 89% after 45 Gy or more.
For residual, inoperable, or recurrent lesions, Wang CC
and Schulz MD [17] reported that the percentage of
patients with controlled symptoms for six months or
more increased with dose (12% with 21-30 Gy, 31% with
31-40 Gy, and 58% with 41-50 Gy). Crane CH et al. [22]
used hypofractionated RT with three different dose regi-
mens (30 Gy/6 fractions, 35 Gy/14 fractions and 45 Gy/
25 fractions). On univariate analysis, BED < 35 Gy10
showed a higher risk of pelvic symptomatic progression
when a/b was assumed to be 10 Gy(p = 0.009). In our
study, the overall symptom control rate and the one-
year symptom control rate were 69% and 40.5% respec-
tively for BED ≥ 40 Gy10 and 32% and 28.5% for BED <
40 Gy10. Since BED was a significant prognostic factor
for symptom control rate, it might be better to treat
with a higher RT dose to increase the palliation rate and
symptom control duration.
In the pelvic cavity, the tolerance dose of normal tis-
sue is a limiting factor when determining the RT dose.
The small bowel, which is regarded as one of the most
sensitive organs to RT, has a tolerance dose of TD 5/5
with a dose of 50 Gy for 1/3 small bowel irradiation and
TD 50/5 with a dose of 60 Gy [33]. The risk of injury to
the bowel is increased in cases with a history of previous
surgery. However, there is evidence suggesting that
significant recovery of the RT effect occurs with time
[23,34]. Nieder C et al. [34] reported that acute respond-
ing tissues recovered from radiation injury within a few
months and could then tolerate another full course of
radiation. For late toxicity endpoints, the skin, mucosa,
lung, and spinal cord do partially recover from subclini-
cal injury at a magnitude dependent on the organ type,
size of the initial dose, and, to a lesser extent, the inter-
val between radiation courses. Mohiuddin M et al. [23]
reported long term results of re-RT for patients with
recurrent rectal cancer. They suggested a re-RT dose
according to the interval between previous RT and re-
RT as follows: 35 Gy for an interval of 3-12 months, 40-
45 Gy for 12-24 months, 45-50 Gy for 24-36 months,
and 50-55 Gy for more than 36 months. In our study,
27% of patients received re-RT, and there was no severe
toxicity, including RT-induced fistula.
Table 2 Symptom recurrences according to patient and
treatment characteristics in patients with palliative
symptom control after palliative treatment
Characteristic Total control
number
Recurrence
(%)
p-value
Symptom
Pain 33 (49) 35 (51) 0.1499
Bleeding 13 (72) 5 (28)
Obstruction 6 (67) 3 (33)
Re-irradiation
Yes 16 (53) 14 (47) 0.8519
No 36 (55) 29 (45)
Biologically equivalent
dose
<4 0G y 10 11 (32) 23 (68) 0.0011
≥40 Gy10 41 (67) 20 (33)
Concurrent
chemotherapy
Yes 14 (44) 8 (36) 0.3387
No 38 (52) 35 (48)
Table 3 Univariate analysis of factors affecting symptom
control rate in 95 cases
Characteristic One-year symptom control
rate (%)
p-value
Age
< 60 years 22.6 0.5121
≥ 60 years 46.8
Gender
Male 45.1 0.1210
Female 29.2
ECOG* performance
status
0-2 36.2 0.8387
3-4 27.0
Primary site
Colon cancer 38.8 0.9967
Rectal cancer 37.8
Symptom
Pain 32.1 0.1029
Bleeding 69.9
Obstruction 37.5
Biologically equivalent
dose
<4 0G y 10 28.5 0.0089
≥ 40 Gy10 40.5
Re-irradiation
Yes 41.0 0.3750
No 36.5
Concurrent
chemotherapy
Yes 61.3 0.0644
No 33.2
Adjuvant chemotherapy
Yes 32.2 0.1986
No 46.8
* ECOG: Eastern Cooperative Oncology Group.
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Figure 2 Symptom control rates according to the biologically equivalent dose (BED) and concurrent chemotherapy during RT (CCRT).
(a) BED more than 40 Gy10 was a statistically significant prognostic factor (p = 0.0089) on univariate analysis in all cases. CCRT was a marginally
significant factor (p = 0.0644) on univariate analysis in all cases. (b) In patients with pain, higher BED and CCRT was associated with improved
outcome with statistical significance. (c) In patients with bleeding, only higher BED was statistically significant factor.
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in patients with distant metastasis. Wong CS et al. [9]
reviewed 519 patients with locally recurrent rectal can-
cer treated with RT. Concurrent extrapelvic distant
metastases were found in 164 patients. Twenty-two
patients received CCRT with 5-fluorouracil and mitomy-
cin C in a pilot study of combined modality therapy.
Ten of the 22 patients were unable to complete the
treatment protocol because of excessive acute hematolo-
gical and gastrointestinal toxicity, and five patients
developed neutropenic sepsis, one of whom died [35].
Crane CH et al. [22] first described the use of CCRT as
an initial measure in 80 patients with synchronous dis-
tant metastasis from rectal cancer. Symptoms from the
primary tumor resolved in 94% of cases, and progression
occurred at a median of 33 weeks. There were acute
complications of Radiation Therapy Oncology Group
(RTOG) Grade 3 or greater in four patients, severe peri-
operative complications in five patients, and no signifi-
cant late treatment-related complications. They
concluded that initial pelvic CCRT produced high pelvic
symptom control rates and that patients can be safely
treated using this modality. In a study of the clinical
benefit of palliative CCRT in advanced gastric cancer,
37 patients were treated with palliative RT (median dose
35 Gy) and nearly two-thirds of all patients received
CCRT [26]. The overall symptom control rate was
approximately 70%, which was superior to the previous
25-54% control rate for palliative RT alone [36]. Some
studies reported the benefit of palliative CCRT for dys-
phagia in advanced esophageal cancer [27-30]. A phase
I/II trial from Canada [29] prospectively treated 22
patients with dysphagia from advanced incurable eso-
phageal cancer with palliative RT (30 Gy/10 Fractions)
and a concurrent single course of chemotherapy (5-FU
and mitomycin-C). Treatment was generally well toler-
ated and 68% achieved a complete response. The med-
ian dysphagia-free interval from time of onset of
improvement was 11 weeks, and 11 patients (73%)
remained dysphagia-free until death. They concluded
that a short course of radiotherapy plus chemotherapy
might produce complete relief of swallowing difficulties
in a substantial proportion of patients with acceptable
toxicity. In our study, the overall symptom control rate
and one-year symptom control rate were 64% and
61.3%, respectively, in CCRT and 52% and 33.2% in RT
alone. There were no severe complications in the CCRT
group.
Our study has some limitation s .F i r s t ,t h i ss t u d yw a s
retrospectively analysis. It had heterogeneous patient’s
group and radiation dose. The results may be affected
by the selection biases. Second, this study was per-
formed in a small sample size. To conclude the effec-
tiveness of the higher BED≥ 40 Gy10 and CCRT to
symptomatic pelvic recurrence, prospective randomized
trial might be needed.
Conclusions
In patients with a pelvic mass combined with distant
metastasis, symptom palliation was achieved in 80% of
the cases, and the median symptom control duration was
five months. For improvement of symptom control rate
and duration, a higher BED ≥ 40 Gy10 is recommended
when possible. Consideringt h el o wm o r b i d i t yw i t h
CCRT and improved symptom palliation, CCRT might
be considered in patients with good performance status.
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